Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06616155
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-31
Brief Title:
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Study of JAK Inhibition in Stem-Like Prostate Cancer JASPER A Phase 1b2a Multicenter Study of Ruxolitinib and Enzalutamide in Castration Resistant Prostate Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase III tests the safety side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production castration-resistant and that has spread from where it first started to other places in the body metastatic Ruxolitinib a kinase inhibitor slows down the growth of the tumor by blocking the proteins JAK1 and JAK2 tumors use to grow Enzalutamide an androgen receptor inhibitor works by blocking the effects of androgen a male reproductive hormone This may help stop the growth and spread of tumor cells that need testosterone to grow Giving ruxolitinib in combination with enzalutamide may be safe tolerable andor effective in treating metastatic castration-resistant prostate cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None